EZM8266

Overview

EZM8266 is an orally active and selective G9a ( EHMT2 ) histone methyltransferase inhibitor with a human EHMT2 IC 50 of 1 pM. EZM8266 reduces repressive H3K9me2 marks at immune-stimulatory gene and endogenous retroviral element promoters. EZM8266 reduces colony formation, migration, and invasion of cancer cells. EZM8266 enhances IFN-γ response, increases MHC class I expression, and enhances CXCL10 -mediated T cell recruitment in cancer cells. EZM8266 can be used for the research of hepatocellular carcinoma.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Histone Methyltransferase

Product Information

• Catalog No.: HY-183058
• CAS No.: 2140164-84-5
• Molecular Formula: C19H27N5O3
• Molecular Weight: 373.45
• Purity: 98.24%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source